Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Princess Máxima Center for Pediatric Oncology, Bilthoven, The Netherlands.
Expert Rev Pharmacoecon Outcomes Res. 2021 Jun;21(3):413-414. doi: 10.1080/14737167.2021.1917385. Epub 2021 May 6.
: Predictive diagnostics play an increasingly important role in personalized medicine for cancer treatment. Whole-genome sequencing (WGS)-based treatment selection is expected to rapidly increase worldwide. This study aimed to calculate and compare the total cost of currently used diagnostic techniques and of WGS in treatment of non-small cell lung carcinoma (NSCLC), melanoma, colorectal cancer (CRC), and gastrointestinal stromal tumor (GIST) in the Netherlands.: The activity-based costing (ABC) method was conducted to calculate total cost of included diagnostic techniques based on data provided by Dutch pathology laboratories and the Dutch-centralized cancer WGS facility. Costs were allocated to four categories: capital costs, maintenance costs, software costs, and operational costs.: The total cost per cancer patient per technique varied from € 58 (Sanger sequencing, three amplicons) to € 2925 (paired tumor-normal WGS). The operational costs accounted for the vast majority (over 90%) of the total per cancer patient technique costs.: This study outlined in detail all costing aspects and cost prices of current and new diagnostic modalities used in treatment of NSCLC, melanoma, CRC, and GIST in the Netherlands. Detailed cost differences and value comparisons between these diagnostic techniques enable future economic evaluations to support decision-making.
: 预测性诊断在癌症治疗的个性化医学中发挥着越来越重要的作用。基于全基因组测序（WGS）的治疗选择预计将在全球范围内迅速增加。本研究旨在计算和比较目前用于非小细胞肺癌（NSCLC）、黑色素瘤、结直肠癌（CRC）和胃肠道间质瘤（GIST）治疗的诊断技术和 WGS 的总成本。: 本研究采用基于活动的成本核算（ABC）方法，根据荷兰病理实验室和荷兰集中式癌症 WGS 机构提供的数据，计算纳入的诊断技术的总成本。成本分配到四个类别：资本成本、维护成本、软件成本和运营成本。: 每种技术的每位癌症患者的总成本从 58 欧元（Sanger 测序，三个扩增子）到 2925 欧元（配对肿瘤-正常 WGS）不等。运营成本占每位癌症患者技术总成本的绝大多数（超过 90%）。: 本研究详细概述了荷兰 NSCLC、黑色素瘤、CRC 和 GIST 治疗中使用的当前和新诊断方式的所有成本方面和成本价格。这些诊断技术之间的详细成本差异和价值比较能够支持未来的经济评估，以支持决策制定。
